CDxDiagnostics_Logo.png
NOTICE TO DISREGARD -- CDx Diagnostics
May 04, 2021 11:13 ET | CDx Diagnostics
SUFFERN, N.Y., May 04, 2021 (GLOBE NEWSWIRE) -- We are advised by CDx Diagnostics that journalists and other readers should disregard the news release, “CDx Diagnostics Contracts with Wellmark Blue...
CDxDiagnostics_Logo.png
WATS3D Receives Medically Necessary Designation from Blue Cross Blue Shield of Kansas City
March 09, 2021 11:00 ET | CDx Diagnostics
SUFFERN, N.Y., March 09, 2021 (GLOBE NEWSWIRE) -- WATS3D, a diagnostic platform used by physicians to detect Barrett’s esophagus (BE), pre-cancer and cancerous cells in the esophagus, has received a...
CDxDiagnostics_Logo.png
WATS3D Now Considered Medically Necessary by BlueCross BlueShield of South Carolina
January 26, 2021 14:00 ET | CDx Diagnostics
SUFFERN, N.Y., Jan. 26, 2021 (GLOBE NEWSWIRE) -- WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to identify precancerous and cancerous cells in the esophagus, is now...
CDxDiagnostics_Logo.png
CDx Diagnostics Awarded Federal Supply Schedule Contract
December 15, 2020 11:30 ET | CDx Diagnostics
Veterans now have access to WATS3D life-saving technology in the VA and community settings SUFFERN, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics has been awarded GSA Contract...
CDxDiagnostics_Logo.png
Study Confirms WATS3D as Cost-Effective Adjunct to Seattle Protocol
August 25, 2020 13:00 ET | CDx Diagnostics
The addition of WATS3D to the screening process for BE resulted in approximately 3 fewer cancers and 3 fewer cancer deaths per 1,000 people screened SUFFERN, N.Y., Aug. 25, 2020 (GLOBE NEWSWIRE) --...
CDxDiagnostics_Logo.png
CDx Diagnostics Announces Contract with Hawaii Medical Services Association
August 11, 2020 14:30 ET | CDx Diagnostics
WATS3D diagnostic platform for screening and surveillance ofBarrett’s esophagus now available to 800,000 members SUFFERN, N.Y., Aug. 11, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics, Inc. is now...
Rafafel_Pharma_PHP_Graphic_Updated_V3
Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer
May 05, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
Cranbury, NJ, May 05, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
Blinded Independent Validation Study Highlights Effectiveness of Tissue Systems Pathology Test in Predicting Risk of Progression to Esophageal Cancer in Patients with Barrett's Esophagus
May 21, 2019 17:15 ET | Cernostics
Data Presented at DDW 2019 Demonstrate Test Potential to Identify Patients Who May Benefit from Increased Surveillance and Early Therapeutic Intervention  PITTSBURGH, PA, May 21, 2019 (GLOBE...
IDXG Logo.jpg
Interpace Diagnostics Enters into Agreement with University of Maryland Medical System
January 14, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
Agreement Provides Access to Company’s Available Molecular Diagnostic Tests PARSIPPANY, NJ, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) has entered in to an...
IDXG Logo.jpg
Interpace Diagnostics CEO Provides Corporate Update
October 10, 2018 08:30 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) is pleased to provide a corporate update to shareholders on current business activities from its Chief...